Product Description
Mechanisms of Action: DNA Damager
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Institut Cancerologie de l'Ouest
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Prostate Cancer|Hypoxia|Adenocarcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT00574353 | N/A |
Completed |
Colorectal Cancer|Hypoxia |
2024-07-05 |
|
| HYPOXProstat | P2 |
Completed |
Adenocarcinoma|Prostate Cancer|Hypoxia |
2014-11-01 |